Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : News Center....FLASH!!!!! -- Ignore unavailable to you. Want to Upgrade?

To: Scott Kelly who wrote (92)	3/16/1998 11:17:00 AM
From: Rande Is	Read Replies (1) \| Respond to of 115

< ADOT >NEWS Just Out: Billion Dollar Cancer Market is Target of New Patented Technology Monday March 16, 10:09 am Eastern Time Company Press Release Billion Dollar Cancer Market is Target of New Patented Technology ALBUQUERQUE, N.M.--(BUSINESS WIRE)--March 16, 1998--Advanced Optics Electronics, Inc. (OTC BB: ADOT - news), today announced major developments from Biomoda, Inc., a medical technology company in which Advanced Optics holds a significant minority interest. Biomoda, Inc. is in final negotiations with a leading cytopathology lab to form a joint venture and begin testing of Biomoda's proprietary sputum diagnostic technology. Biomoda, Inc. is anticipating its effective cancer testing/treatment program will enter the public market the end of the second quarter of 1999. Biomoda will initially pursue market share in the $3 billion lung cancer market and later in the $750 million inflammatory bowel disease market. Biomoda's application of porphyrin compounds to cancer therapies is an area of intense pharmaceutical research and development. Biomoda currently stands alone as the only company with a patented early detection test (able to detect lung cancer at least six years earlier than any other test) and an integrated treatment program. Biomoda's treatment program is effective on both surface cancers and internal cancers. The licensed technology of Biomoda, Inc. is based on patented applications of TCPP, a synthetic porphyrin compound for cancer diagnostics and cancer therapeutics. When used outside the body for clinical diagnosis of sputum, TCPP binds to lung cancer cells and can be detected with a fluorescent microscope. When used inside the body, TCPP (joined to a copper isotope, CU-67) accumulates in the affected region of the lungs. The gamma rays emitted from the CU-67 can attack tumors on a very deep level. The use of the same compound, TCPP, outside and inside the body, leads to Biomoda's unique, integrated, medical strategy. Biomoda anticipates revenues on the testing alone to exceed $70 million in year five. Advanced Optics is extremely pleased with the scientific and financial potential resident in Biomoda's proprietary program. Advanced Optics further believes its investment in the recent developments at Biomoda is capable of yielding tremendous benefits to the shareholders of Advanced Optics Electronics, Inc. (ADOT). Advanced Optics Electronics also announced today, exciting news regarding their revolutionary flat panel display billboards. These billboards are capable of ''television type'' advertising and utilize Advanced Optics patented technology. In addition to the current orders for two displays (totaling $1.7 million) which are in production, the Company has recently received requests for additional displays totaling $2.7 million. An Advanced Optics company spokesman had high praise for the rapid rate of progress at the Company. ''Our aggressive business approach, in the areas of flat panel display production and the medical breakthroughs being made by Biomoda, could enable us to exceed our own high expectations.'' The Company spokesman concluded by saying, ''Our technology for flat panel displays is on technology's leading edge. This technology can also be used to assist in the optical design portion of equipment used in Biomoda's cancer testing and treatment program. We are truly looking forward to both the financial and humanitarian benefits available to us.'' This press release contains forward-looking statements with respect to the results of operations and business of the Company that involves risk and uncertainties. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports to be filed with the Securities and Exchange Commission. Contact: Advanced Optics Electronics, Inc. (505) 797-7878 www.adot.org.